Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials

<div>Secondary efficacy outcomes of guselkumab in the treatment of plaque psoriasis versus placebo or adalimumab. PASI: Psoriasis Area and Severity Index.</div>

Journal of Immunology Research

fig4

Figure 4

Figure 4: Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials 

Figure 4 | Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials 